See more : NEXT plc (NXT.L) Income Statement Analysis – Financial Results
Complete financial analysis of Ampio Pharmaceuticals, Inc. (AMPE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ampio Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sichuan Hexie Shuangma Co., Ltd. (000935.SZ) Income Statement Analysis – Financial Results
- Permanent TSB Group Holdings plc (PTSB.IR) Income Statement Analysis – Financial Results
- Varopakorn Public Company Limited (VARO.BK) Income Statement Analysis – Financial Results
- Voltalia SA (0QW7.L) Income Statement Analysis – Financial Results
- bonyf N.V. (MLBON.PA) Income Statement Analysis – Financial Results
Ampio Pharmaceuticals, Inc. (AMPE)
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 76.79K | 50.00K | 50.00K | 18.75K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 250.00K | 2.08M | 1.09M | 1.18M | 1.27M | 523.00K | 568.00K | 950.00K | 369.31K | 2.24M | 1.74M | 1.45M | 0.00 | 0.00 | 0.00 | 950.00 | 0.00 | 0.00 |
| Gross Profit | -250.00K | -2.08M | -1.09M | -1.18M | -1.27M | -523.00K | -568.00K | -950.00K | 793.15K | -2.16M | -1.69M | -1.40M | 18.75K | 0.00 | 0.00 | -950.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 68.23% | -2,818.46% | -3,376.00% | -2,798.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.44M | 8.92M | 11.90M | 9.17M | 12.62M | 6.83M | 10.42M | 10.55M | 18.96M | 26.92M | 18.29M | 7.49M | 6.65M | 1.97M | 1.07M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.08M | 11.47M | 8.67M | 6.65M | 5.90M | 4.36M | 5.14M | 6.54M | 15.14M | 12.23M | 5.79M | 4.38M | 4.50M | 4.73M | 21.87K | 28.28K | 27.80K | 0.00 |
| Other Expenses | 0.00 | 1.94M | 0.00 | 12.00K | 56.00K | 0.00 | 323.55K | 143.80K | 0.00 | 0.00 | 0.00 | 0.00 | 34.01K | 0.00 | 0.00 | 950.00 | 1.20K | 0.00 |
| Operating Expenses | 9.27M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.10M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Cost & Expenses | 9.52M | 20.38M | 20.57M | 15.83M | 18.58M | 11.18M | 15.56M | 17.08M | 34.46M | 39.15M | 24.07M | 11.87M | 11.15M | 6.70M | 21.87K | 29.23K | 29.00K | 1.00K |
| Interest Income | 348.00K | 220.00K | 4.00K | 12.00K | 77.00K | 5.00K | 3.09K | 23.48K | 59.85K | 22.26K | 12.29K | 21.94K | 6.68K | 815.00 | 1.09K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.36K | 19.55K | 4.18K | 2.65K | 0.00 | 0.00 |
| Depreciation & Amortization | 127.00K | 2.08M | 1.09M | 1.18M | 1.27M | 1.28M | 1.21M | 1.21M | 1.14M | 439.10K | 137.68K | 62.40K | 42.55K | 815.00 | 0.00 | 0.00 | 2.19K | 0.00 |
| EBITDA | 0.00 | -18.30M | 0.00 | 0.00 | -17.30M | 35.26M | -14.46M | -14.81M | -23.34M | 0.00 | -23.89M | -11.76M | -11.08M | -8.01M | -21.87K | -29.23K | -26.81K | -1.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,760.35% | -50,310.73% | -47,747.81% | -23,472.97% | -59,119.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.52M | -24.21M | -25.16M | -15.22M | -23.45M | -11.18M | -15.56M | -17.08M | -33.30M | -39.07M | -24.02M | -11.82M | -11.13M | -6.70M | -21.87K | -29.23K | -29.00K | -1.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,864.79% | -50,882.57% | -48,047.74% | -23,641.65% | -59,382.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 886.00K | 4.05M | 3.50M | -60.00K | 4.95M | 45.17M | -36.22M | -2.08M | -412.07K | -7.60M | -504.16K | 227.29K | -7.14M | -1.35M | -4.18K | -2.65K | -2.19K | 0.00 |
| Income Before Tax | -8.63M | -16.34M | -17.08M | -15.89M | -13.63M | 33.99M | -51.89M | -19.16M | -33.71M | -39.05M | -24.53M | -11.59M | -18.28M | -8.05M | -26.05K | -31.88K | -31.20K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,900.24% | -50,853.58% | -49,056.85% | -23,186.23% | -97,475.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.87M | -4.59M | 604.00K | -4.95M | 45.17M | 36.33M | 1.04M | -1.29M | -923.52K | -519.87K | -68.00 | 82.50K | 18.73K | 0.00 | 0.00 | 800.00 | 1.00K |
| Net Income | -8.63M | -8.47M | -12.49M | -16.50M | -8.68M | 33.99M | -51.89M | -19.16M | -32.01M | -38.13M | -24.01M | -11.59M | -18.36M | -8.05M | -26.05K | -31.88K | -32.00K | -1.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,753.66% | -49,650.87% | -48,017.12% | -23,186.09% | -97,915.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -10.67 | -11.24 | -18.79 | -28.63 | -18.32 | 92.10 | -239.13 | -107.06 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| EPS Diluted | -10.66 | -11.24 | -18.59 | -27.71 | -18.32 | 91.90 | -238.41 | -106.91 | -184.70 | -227.72 | -188.09 | -102.34 | -211.73 | -137.54 | -0.53 | -0.51 | -0.52 | -0.02 |
| Weighted Avg Shares Out | 809.00K | 753.62K | 664.33K | 576.16K | 474.03K | 369.00K | 217.00K | 179.00K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
| Weighted Avg Shares Out (Dil) | 810.11K | 753.62K | 671.49K | 595.41K | 474.03K | 369.81K | 217.66K | 179.24K | 173.31K | 167.42K | 127.65K | 113.28K | 86.71K | 58.56K | 49.31K | 61.98K | 61.98K | 61.98K |
Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call Transcript
Ampio Pharmaceuticals Strengthens Management Team and Board of Directors
ENGLEWOOD, Colo., Oct. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointments of Howard Levy, M.B.B.Ch.
Ampio Pharmaceuticals Receives Approval from the Drugs Controller General of India (DCGI) to Commence AP-019 Phase II Study in India
ENGLEWOOD, Colo., Sept. 21, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced regulatory approval from the Drugs Controller General of India (DCGI) of the Central...
Best Penny Stocks For Retail Traders to Buy? 3 For Your List
Investing in penny stocks right now? Check these three small caps out for your watchlist The post Best Penny Stocks For Retail Traders to Buy?
Penny Stocks For Your Biotech Watch List In September 2021
Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)
ENGLEWOOD, Colo., Sept. 15, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced top-line results from AP-013, a randomized, saline-controlled, double-blind Phase III clinical study...
Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action
ENGLEWOOD, Colo., Aug. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced a preprint version of...
Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting
ENGLEWOOD, Colo., Aug. 12, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, reminds stockholders to vote on the...
Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
ENGLEWOOD, Colo., Aug. 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that the company will...
Why Penny Stocks Investors Are Bullish on These 3 Small-Caps
Why penny stocks investors are showing bullish interest in these 3 small-caps The post Why Penny Stocks Investors Are Bullish on These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports